Poseida Therapeutics, Inc. (PSTX) Financial Analysis & Valuation | Quarter Chart
Poseida Therapeutics, Inc. (PSTX)
PSTXPrice: $9.5
Fair Value: 🔒
🔒score
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment ... more
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therap... more
Description
Shares
| Market Cap | $925.93M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Mark J. Gergen |
| IPO Date | 2020-07-10 | CAGR | 0.31% |
| Employees | 350 | Website | www.poseida.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.05% | Total Yield | -0.05% |
PSTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $311.27M | P/E Ratio | -15.08 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 9.48 | P/B Ratio | 10.58 |
| P/CF Ratio | 31.99 | P/FCF Ratio | 34.05 |
| EPS | $-0.63 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 203.97% | Gross Margin | 0.99% |
| Operating Margin | -0.12% | Profit Margin | -0.11% |
| ROE | -0.15% | ROA | -0.04% |
| ROCE | -0.06% | Current Ratio | 3.2 |
| Quick Ratio | 3.2 | Cash Ratio | 0.63 |
| Debt/Equity | 0.95 | Interest Coverage | -2.64 |
| Altman Z Score | 0.33 | Piotroski Score | 4 |